• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

The CREOLE trial: amlodipine and either hydrochlorothiazide or perindopril optimally lowers blood pressure in black African patients

byDayton McMillan
June 23, 2019
in Cardiology, Chronic Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Black African patients with hypertension randomized to multiple two-drug combinations experienced greater blood pressure control when treated with amlodipine plus either hydrochlorothiazide or perindopril compared to those treated with perindopril plus hydrochlorothiazide.

2. Adverse event rates were similar in all three treatment groups.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Hypertension is the most notable contributor to global disease burden, and blood pressure control can notably reduce morbidity and mortality. To reach blood pressures of less than 140/90 mmHg, duel therapy is often needed. Hypertensive therapies recommended for black African patients differ in the United States and Europe, thus more definitive studies comparing therapeutic options are needed. The Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans (CREOLE) trial evaluated various combinations of a calcium-channel blocker (amlodipine), thiazide diuretic (hydrochlorothiazide), and angiotensin-converting–enzyme (ACE) inhibitor (perindopril). The primary end-point of change in 24-hour systolic blood pressure between baseline and after 6 months of treatment showed the use of amlodipine plus either hydrochlorothiazide or perindopril were similarly effective, and more effective than perindopril plus hydrochlorothiazide.

Strengths of the study include its use of 24-hour blood pressure monitoring and evaluation of multiple two-drug therapies, while the study is limited by its lack of statistical adjustment for multiple comparison testing.

Click to read the study in NEJM

Relevant Reading: Physiological phenotyping for personalized therapy of uncontrolled hypertension in Africa

RELATED REPORTS

Treating mild chronic hypertension associated with better pregnancy outcome

Radiofrequency renal denervation produces long-lasting reductions in blood pressure

Intensive blood pressure control associated with increased cerebral blood flow in patients with hypertension – the SPRINT trial

In-Depth [randomized controlled trial]: This randomized controlled trial enrolled patients between June and December 2017 in 6 sub-Saharan African countries. Eligible patients were black, between the ages of 30 and 79, had not received prior hypertensive treatment and had a systolic blood pressure of between 150 and 179 mmHg when seated at an office visit, or when on monotherapy and had a systolic blood pressure of between 140 and 159 mmHg. Patients who were pregnant or with a history of secondary hypertension or cardiovascular disease were excluded from the study. At baseline and after 6 months of treatment, patients had 24-hour blood pressures taken. Randomization into three groups was done in a 1:1:1 manner: 5mg amlodipine plus 12.5mg hydrochlorothiazide daily (n=216), 5mg amlodipine plus 4mg perindopril daily (n=205), or 4mg perindopril plus 12.5mg hydrochlorothiazide daily (n=200). After 2 months, doses were doubled unless patients had unacceptable side effects. The primary end point of mean change in systolic blood pressure between baseline and 6 months was −3.14 mmHg (95% confidence interval [CI], −5.90 to −0.38; P=0.03) for the amlodipine/hydrochlorothiazide group compared to the perindopril/hydrochlorothiazide group. For the amlodipine/perindopril group, the mean change was −3.00 mmHg (95% CI, −5.81 to −0.20 mm Hg; P = 0.04) compared to the perindopril/hydrochlorothiazide group. Reductions in office measured systolic blood pressures were greater in patients receiving amlodipine as well, and the difference was greater than in the 24-hour measurements. Adherence to treatment medications was similar in all three groups, and rates of adverse effects were also similar in all three groups.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: ACE inhibitorsamlodipineblood pressurecalcium channel blocker (CCB)hydrochlorothiazidehypertensionperindoprilthiazide diuretic
Previous Post

#VisualAbstract: Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa

Next Post

Quick Take: HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception

RelatedReports

Prenatal antidepressant exposure may increase risk of poor motor development
Cardiology

Treating mild chronic hypertension associated with better pregnancy outcome

May 13, 2022
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Cardiology

Radiofrequency renal denervation produces long-lasting reductions in blood pressure

April 20, 2022
Parental nonmedical prescription opioid use linked to adolescent use
Cardiology

Intensive blood pressure control associated with increased cerebral blood flow in patients with hypertension – the SPRINT trial

March 8, 2022
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Weekly Rewinds

2 Minute Medicine Rewind February 14, 2022

February 14, 2022
Next Post
Government-funded initiatives provide important supports to low-income HIV patients

Quick Take: HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study

Quick Take: Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups

Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities

Evobrutinib reduces imaging findings of multiple sclerosis but not clinical progression

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.